Astellas Pharma Inc. and XenoPort, Inc. (XNPT) Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome
11/19/2009 8:44:56 AM
More...
|
GlaxoSmithKline (GSK) (JOBS) and XenoPort, Inc. (XNPT) Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
11/9/2009 6:59:59 AM
More...
|
XenoPort, Inc. (XNPT) to Release Third Quarter Financial Results on November 3, 2009
10/29/2009 11:42:37 AM
More...
|
XenoPort, Inc. (XNPT) Announces Initiation of a Phase 2b Clinical Trial of Arbaclofen Placarbil in Patients with Gastroesophageal Reflux Disease
10/19/2009 9:25:29 AM
More...
|
XenoPort, Inc. (XNPT), GlaxoSmithKline (GSK) (JOBS) Says Pain Drug Meets Main Goal of Trial
9/18/2009 7:06:10 AM
More...
|
XenoPort, Inc. (XNPT) to Present at Upcoming Conferences
9/9/2009 1:45:53 PM
More...
|
XenoPort, Inc. (XNPT) Reports Preliminary Results From a Safety and Tolerability Trial of Arbaclofen Placarbil in Patients With Acute Back Spasms
9/8/2009 10:20:31 AM
More...
|
XenoPort, Inc. (XNPT) Appoints Dennis Fenton to Board
8/13/2009 9:00:36 AM
More...
|
XenoPort, Inc. (XNPT) Reports Second Quarter Financial Results
8/6/2009 9:36:38 AM
More...
|
XenoPort, Inc. (XNPT) Announces Astellas Pharma Inc. Plans to File an NDA for XP13512 in Japan
8/4/2009 10:05:57 AM
More...
|
|